AVDL · As filed with the SEC
Avadel Pharmaceuticals income statement, by fiscal year
The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Loss · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Net product revenue | 169,117 | 27,963 | 0 | 0 |
| Cost of products sold | 15,277 | 846 | 0 | 0 |
| Gross profit | 153,840 | 27,117 | 0 | 0 |
| Operating expenses: | ||||
| Research and development expenses | 15,196 | 13,261 | 20,700 | 17,104 |
| Selling, general and administrative expenses | 181,043 | 151,705 | 74,516 | 68,495 |
| Restructuring expense | 0 | 0 | 3,345 | (53) |
| Total operating expenses | 196,239 | 164,966 | 98,561 | 85,546 |
| Operating loss | (42,399) | (137,849) | (98,561) | (85,546) |
| Investment and other income (expense), net | 4,150 | 87 | (536) | 2,343 |
| Interest expense | (10,830) | (9,886) | (12,342) | (9,942) |
| Loss on extinguishment of debt | 0 | (13,129) | 0 | 0 |
| Loss before income taxes | (49,079) | (160,777) | (111,439) | (93,145) |
| Income tax (benefit) provision | (247) | (501) | 26,025 | (15,816) |
| Net loss | (48,832) | (160,276) | (137,464) | (77,329) |
| Net loss per share - basic (in dollars per share) | (0.51) | (2.00) | (2.29) | (1.32) |
| Net loss per share - diluted (in dollars per share) | (0.51) | (2.00) | (2.29) | (1.32) |
| Weighted average number of shares outstanding - basic (in shares) | 95,141 | 80,174 | 60,094 | 58,535 |
| Weighted average number of shares outstanding - diluted (in shares) | 95,141 | 80,174 | 60,094 | 58,535 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.